A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
This study has been completed.
Information provided by (Responsible Party):
First received: June 11, 2010
Last updated: September 8, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||May 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||March 12, 2014|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC; REVERSE Study Investigators. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology. 2016 Jun;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026. Epub 2016 Feb 16.